Life Science Nation Newsletter  | September 22,  2016  |  Issue 180

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Sept. 15  - Sept. 21)
Invests in Diagnostics and Research Tools in Oncology, Hemotology, Pain and Cardiology
Seeks Biopharma, Med Device, Diagnostic and Mobile Health Deals Worldwide
Seeks Commercial-Stage Healthcare IT and Medtech Deals
Seeks Pre-Clinical Therapeutics, Diagnostics and Devices
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI on MaRS Investors Panel

By Caitlin Kramer, Research Analyst, LSN

RESI X featured the arrival of a new panel session - Big Data in Healthcare.  If you were unable to attend, you will have another opportunity to hear insights from investors and influencers in the space at RESI SF on January 10th.

The panel, available for your viewing below, was moderated by Nicole Fisher (Founder & CEO, HHR Strategies) and featured the thoughts and experiences of:
  • Alex De Winter, Director, GE Ventures
  • Allyson Plosko, Sector Manager - Healthcare, Village Capital Investments
  • Annie Hazlehurst, Founder, Faridan
  • Dylan Morris, Investment Team, Innovation Endeavors
  • Linda Pan, Program Director, Partnerships & Solutions, IBM Watson Ecosystem
Each discussed the unique approaches their firms take toward evaluating big data and software investment opportunities, how they partner with and shape start-up growth, and how the healthcare system landscape is (or is not) shifting to enable a realization of the big data vision...

With summer now behind us, the world's biotech and medtech community is counting down to the San Francisco healthcare conference season. If you're making your JPM plans now, it's definitely time to apply to the RESI Innovation Challenge.

LSN's scientific team is preparing to review the RESI Innovation Challenge applications from biotech, medtech, diagnostic and healthcare IT companies. Successful applicants will be provided with an all-day display space for their startup company at RESI - and with the heavy foot traffic at JPM, there's never been a better opportunity to win investor exposure for your new technology. All applicants are vetted by LSN's scientific review team, with a view to not just the quality of the company's scientific work, but also the strength of the management team and how well-positioned the company is to receive investment...

By Nono Hu, Director of Marketing, LSN

Following the overview of the fundraising process in Chapter 12, we get into some of the nitty-gritty areas and explore a few common pitfalls and how to avoid them. Chapter 13 discusses the importance of getting on the road or hitting the phone to engage with relevant investors, and why it's important to ensure that all the investor prospects you speak with are kept in context regarding the deal. Finally, the chapter explores how to prioritize your prospects to use your runway time most effectively while raising money.